

THE PHARMACY LIBRARY

SE 1 5 '92

JOURNAL OF  
**MEDICINAL  
CHEMISTRY**

SEPTEMBER 4, 1992  
VOLUME 35 • NUMBER 18  
AMERICAN CHEMICAL SOCIETY

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).



JOURNAL OF  
**MEDICINAL  
CHEMISTRY**

**EDITOR-IN-CHIEF**

PHILIP S. PORTOGHESE

Department of Medicinal Chemistry  
College of Pharmacy, Room 8-114  
University of Minnesota  
308 Harvard St. S.E.  
Minneapolis, Minnesota 55455  
(612) 624-6184  
FAX (612) 626-6891

**SENIOR EDITORS**

Raymond E. Counsell  
Laurence H. Hurley  
Herbert T. Nagasawa  
Wendel L. Nelson

**Book Review Editor**

Carl Kaiser

**EDITORIAL ADVISORY BOARD**

Stephen J. Benkovic  
Ronald T. Borchardt  
Arthur D. Broom  
James K. Coward  
Peter B. Dervan  
Stephen W. Fesik  
David S. Fries  
Ralph F. Hirschmann  
M. Ross Johnson  
Michael Marletta  
David A. Matthews  
Duane Miller  
John H. Musser  
John L. Neumeyer  
William Prusoff  
Kenner C. Rice  
C. H. Robinson  
Robert R. Ruffolo, Jr.  
Stuart Schreiber  
John A. Secrist, III  
Robert P. Sheridan  
David J. Triggle  
Daniel F. Veber  
Michael Williams  
Dennis M. Zimmerman  
*Ex officio:* William F. Johns

American Chemical Society  
1155 16th St., N.W.  
Washington, DC 20036  
(202) 872-4600  
TDD (202) 872-8733  
FAX (202) 872-4615

**Journals Department**

American Chemical Society  
2540 Olentangy River Road  
P.O. Box 3330  
Columbus, OH 43210  
(614) 447-3600, Ext. 3171  
TELEX 6842086; FAX (614) 447-3745

**Member & Subscriber Services**

American Chemical Society  
P.O. Box 3337  
Columbus, OH 43210  
(614) 447-3776; FAX (614) 447-3671

*Journal of Medicinal Chemistry* (ISSN 0022-2623) is published biweekly by the American Chemical Society at 1155 16th St., N.W., Washington, DC 20036. Second-class postage paid at Washington, DC, and additional mailing offices. POSTMASTER: Send address changes to *Journal of Medicinal Chemistry*, Member & Subscriber Services, P.O. Box 3337, Columbus, OH 43210. Canadian GST Reg. No. R127571347.

**PUBLICATIONS DIVISION**

Robert H. Marks, Director

*Journals Department:* Charles R. Bertsch, Head; Marianne C. Brogan, Associate Head

*Editorial Office:* Mary E. Scanlan, Manager; Kathleen E. Duffy, Joseph E. Yurvati, Journals Editing Managers; Anne C. O'Melia, Senior Associate Editor; Mary Jo Lesheski, Lee S. Thurston, and Margaret A. Winship, Assistant Editors

Advertising Office: Centcom, Ltd., 1599 Post Road East, P.O. Box 231, Westport, CT 06881

© Copyright 1992 by the American Chemical Society. **Copyright permission:** An individual may make a single reprographic copy of an article in this publication for personal use. Reprographic copying beyond that permitted by Section 107 or 108 of the U.S. Copyright Law is allowed, provided that the appropriate per-copy fee is paid through the Copyright Clearance Center, Inc., 27 Congress St., Salem, MA 01970. For reprint permission, please write to the Copyright Administrator, Publications Division, at the ACS Washington address.

The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

**Editorial Information**

**Instructions for authors** and copyright transfer form are printed in the first issue of each volume. Please conform to these instructions when submitting manuscripts.

**Manuscripts for publication** should be submitted to the Editor, Philip S. Portoghesi, at his Minneapolis address.

Correspondence regarding **accepted papers and proofs** should be directed to the Journals Department, at the address below.

**Page charges** of \$25.00 per page may be paid for papers published in this journal. Payment does not affect acceptance or scheduling of papers.

**Bulk reprints** of individual articles are available. For information write to Distribution Office at the ACS Washington address.

The American Chemical Society and its Editors assume no responsibility for the statements and opinions advanced by contributors.

Registered names and trademarks, etc., used in this publication, even without specific indication thereof, are not to

**Subscription and Business Information**

**1992 subscription prices**, including postage. (For membership information, contact Office of Member Services at the ACS Washington address.)

	U.S.	Canada and Mexico	Europe*	All Other Countries*
<b>Printed</b>				
Members—1 yr	\$ 49	\$ 80	\$108	\$131
2 yr	\$ 88	\$150	\$206	\$252
Nonmembers	\$497	\$528	\$556	\$579
<b>Microfiche</b>				
Members—1 yr	\$ 49	\$ 49	\$ 69	\$ 69
2 yr	\$ 88	\$ 88	\$128	\$128
Nonmembers	\$497	\$497	\$517	\$517
Supplementary material (microfiche)	\$ 30	\$ 45	\$ 45	\$ 45

\* Air service included.

**New and renewal subscriptions** should be sent with payment to American Chemical Society, Department L-0011, Columbus, OH 43268-0011. Subscriptions are available only on a calendar year basis. Rates quoted do not apply to nonmember subscribers in Japan, who must enter subscription orders with Maruzen Company Ltd., 3-10 Nihonbashi 2-chome, Chuo-ku, Tokyo 103, Japan. Tel: (03) 272-7211.

**Printed edition single issue prices:** current year, \$20.00; prior year, \$45.00. **Back volume price:** \$531.00. Foreign postage additional. Mail orders should be sent to Microforms & Back Issues Office at the ACS Washington address.

**Phone orders** can be placed for printed, microfiche, and microfilm editions by calling the ACS toll free at (800) 333-9511 from anywhere in the United States and Canada; elsewhere call (614) 447-3776. Phone orders can be charged to Visa, MasterCard, or American Express accounts.

**Changes of address** must include both old and new addresses with ZIP code and a recent mailing label. Send all address changes to Member & Subscriber Services. Please allow 6 weeks for change to become effective.

**Claims for missing numbers** will not be allowed if loss was due to failure of notice of change of address to be received in the time specified; if claim is dated (a) North America—more than 90 days beyond issue date, (b) all other foreign—more than 180 days beyond issue date. Hard copy claims are handled by Member & Subscriber Services.

**Supplementary material** is noted in the table of contents with a ■. It is available as photocopy (\$10.00 for up to 3 pages and \$1.50 per page for additional pages, plus \$2.00 for foreign postage) or as 24× microfiche (\$10.00, plus \$1.00 for foreign postage). Canadian residents should add 7% GST. See supplementary material notice at end of journal article for number of pages. Orders *must* state whether for photocopy or for microfiche and give complete title of article, names of authors, journal, issue date, and page numbers. Prepayment is required and prices are subject to change. Order from Microforms & Back Issues Office at the ACS Washington address. Supplementary material except structure factors also appears in the microfilm edition and may be ordered by subscription (in microfiche

JOURNAL OF  
**MEDICINAL  
CHEMISTRY**<sup>®</sup>

Registered in U.S. Patent and Trademark Office  
© Copyright 1992 by the American Chemical Society

Volume 35, Number 18  
September 4, 1992

JMCMAR 35(18) 3307-3428 (1992)  
ISSN 0022-2623

COMMUNICATIONS TO THE EDITOR

- 3423 3-Phenyl-4-hydroxyquinolin-2(1*H*)-ones: Potent and Selective Antagonists at the Strychnine-Insensitive Glycine Site on the *N*-Methyl-D-aspartate Receptor Complex  
Loretta A. McQuaid,\* Edward C. R. Smith, David Lodge, Etienne Pralong, James H. Wikel, David O. Calligaro, and Patrick J. O'Malley
- 3426 Specific Inhibition of HIV-1 Protease by Boronated Porphyrins  
■ Dianne L. DeCamp, Lilia M. Babé, Rafael Salto, Jeanne L. Lucich, Myoung-Seo Koo, Stephen B. Kahl,\* and Charles S. Craik\*

ARTICLES

- 3307 Novel 5-HT<sub>3</sub> Antagonists. Isoquinolinones and 3-Aryl-2-pyridones  
Toshiaki Matsui, Tsuneyuki Sugiura, Hisao Nakai,\* Sadahiko Iguchi, Satoshi Shigeoka, Hideo Takada, Yoshihiko Odagaki, Yuhki Nagao, Yasuyuki Ushio, Kazuyuki Ohmoto, Hiroyuki Iwamura, Shinichi Yamazaki, Yoshinobu Arai, and Masanori Kawamura
- 3319 Synthesis and Excitatory Amino Acid Pharmacology of a Series of Heterocyclic-Fused Quinoxalinones and Quinazolinones  
Loretta A. McQuaid,\* Edward C. R. Smith, Kimberly K. South, Charles H. Mitch, Darryle D. Schoepp, Rebecca A. True, David O. Calligaro, Patrick J. O'Malley, David Lodge, and Paul L. Ornstein
- 3325 Synthesis and Pharmacological Studies of *N*-Substituted 6-[(2-Aminoethyl)amino]-1,3-dimethyl-2,4(1*H*,3*H*)-pyrimidinediones, Novel Class III Antiarrhythmic Agents  
Tsutomu Katakami,\* Tatsuro Yokoyama, Michihiko Miyamoto, Haruki Mori, Nobuya Kawauchi, Tadahito Nobori, Kunio San-nohe, Tatsuo Kaiho,\* and Joji Kamiya
- 3331 Synthesis of a Homologous Series of Ketomethylene Arginyl Pseudodipeptides and Application to Low Molecular Weight Hirudin-like Thrombin Inhibitors  
John DiMaio,\* Bernard Gibbs, Jean Lefebvre, Yasuo Konishi, Debra Munn, Shi Yi Yue, and Wilfried Hornberger
- 3341 Determination of the Absolute Configuration of the Active Amlodipine Enantiomer as (-)-*S*: A Correction  
■ Siegfried Goldmann,\* Jürgen Stoltefuss, and Liborius Born
- 3344 Synthesis and Functional Evaluation of a Peptide Derivative of 1-β-D-Arabinofuranosylcytosine  
Zoltán Balajthy,\* János Aradi, Ildikó T. Kiss, and Pál Elődi
- 3349 *cis*-Bis(pyridine)platinum(II) Organoamides with Unexpected Growth Inhibition Properties and Antitumor Activity  
Lorraine K. Webster,\* Glen B. Deacon,\* David P. Buxton, Brian L. Hillcoat, Alison M. James, Ian A. G. Roos, Robin J. Thomson, Laurence P. G. Wakelin, and Tracey L. Williams
- 3353 Synthesis and Antibronchospastic Activity of 8-Alkoxy- and 8-(Alkylamino)imidazo[1,2-*a*]pyrazines  
Pierre A. Bonnet, Alain Michel, Florence Laurent, Claire Sablayrolles, Eliane Rechencq, Jean C. Mani, Maurice Boucard, and Jean P. Chapat\*
- 3358 Synthesis and Chemical Characterization of *N*-Substituted Phenoxazines Directed toward Reversing Vinca Alkaloid Resistance in Multidrug-Resistant Cancer Cells  
Kuntebommanahalli N. Thimmaiah, Julie K. Horton, Ramakrishnan Seshadri, Mervyn Israel, Janet A. Houghton, Franklin C. Harwood, and Peter J. Houghton\*



- 3364 Synthesis and Biological Activity of Ketomethylene Pseudopeptide Analogues as Thrombin Inhibitors  
Leifeng Cheng,\* Christopher A. Goodwin, Michael F. Schully, Vijay V. Kakkar, and Göran Claeson\*
- 3369 3',3'-Difluoro-3'-deoxythymidine: Comparison of Anti-HIV Activity to 3'-Fluoro-3'-deoxythymidine  
Donald E. Bergstrom,\* Andrew W. Mott, Erik De Clercq, Jan Balzarini, and Daniel J. Swartling
- 3372 Synthesis and Antiviral Properties of ( $\pm$ )-5'-Noraristeromycin and Related Purine Carbocyclic Nucleosides. A New Lead for Anti-Human Cytomegalovirus Agent Design  
Sharadbala D. Patil, Stewart W. Schneller,\* Mitsuaki Hosoya, Robert Snoeck, Graciela Andrei, Jan Balzarini, and Erik De Clercq
- 3377 Antitumor Imidazotetrazines. 25. Crystal Structure of 8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (Temozolomide) and Structural Comparisons with the Related Drugs Mitozolomide and DTIC  
P. R. Lowe, C. E. Sansom, C. H. Schwalbe,\* M. F. G. Stevens, and A. S. Clark
- 3382 Energy Aspects of Oil/Water Partition Leading to the Novel Hydrophobic Parameters for the Analysis of Quantitative Structure-Activity Relationships  
Yong-Zhong Da, Katsuhiko Ito, and Hideaki Fujiwara\*
- 3388 Synthesis and Biological Evaluation of Dihydroeptastatin, a Novel Inhibitor of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase  
Elisabeth A. Bone, Alan H. Davidson, Christopher N. Lewis,\* and Richard S. Todd
- 3394 Non-Prostanoid Thromboxane A<sub>2</sub> Receptor Antagonists with a Dibenzoxepin Ring System. 1  
Etsuo Ohshima, Hitoshi Takami, Hideyuki Sato, Hiroyuki Obase,\* Ichiro Miki, Akio Ishii, Akira Karasawa, and Kazuhiro Kubo
- 3402 Non-Prostanoid Thromboxane A<sub>2</sub> Receptor Antagonists with a Dibenzoxepin Ring System. 2  
Etsuo Ohshima, Hitoshi Takami, Hideyuki Sato, Shinichiro Mohri, Hiroyuki Obase,\* Ichiro Miki, Akio Ishii, Shiro Shirakura, Akira Karasawa, and Kazuhiro Kubo
- 3413 Reversible Inhibitors of the Gastric (H<sup>+</sup>/K<sup>+</sup>)-ATPase. 3. 3-Substituted-4-(phenylamino)quinolines  
Robert J. Ife,\* Thomas H. Brown, David J. Keeling, Colin A. Leach, Malcolm L. Meeson, Michael E. Parsons, David R. Reavill, Colin J. Theobald, and Kenneth J. Wiggall

■ Supplementary material for this paper is available separately (consult the masthead page for ordering information); all supplementary material except structure factor tables will also appear following the paper in the microfilm edition of this journal.

\* In papers with more than one author, the asterisk indicates the name of the author to whom inquiries about the paper should be addressed.

## AUTHOR INDEX

- |                              |                          |                            |                             |                             |
|------------------------------|--------------------------|----------------------------|-----------------------------|-----------------------------|
| Andrei, G., 3372             | Elödi, P., 3344          | Katakami, T., 3325         | Nagao, Y., 3307             | Shigeoka, S., 3307          |
| Aradi, J., 3344              | Fujiwara, H., 3382       | Kawamura, M., 3307         | Nakai, H., 3307             | Shirakura, S., 3402         |
| Arai, Y., 3307               | Gibbs, B., 3331          | Kawauchi, N., 3325         | Nobori, T., 3325            | Smith, E. C. R., 3319, 3423 |
| Babé, L. M., 3426            | Goldmann, S., 3341       | Keeling, D. J., 3413       | Obase, H., 3394, 3402       | Snoeck, R., 3372            |
| Balajthy, Z., 3344           | Goodwin, C. A., 3364     | Kiss, I. T., 3344          | Odagaki, Y., 3307           | South, K. K., 3319          |
| Balzarini, J., 3369, 3372    | Harwood, F. C., 3358     | Konishi, Y., 3331          | Ohmoto, K., 3307            | Stevens, M. F. G., 3377     |
| Bergstrom, D. E., 3369       | Hillcoat, B. L., 3349    | Koo, M.-S., 3426           | Ohshima, E., 3394, 3402     | Stoltefuss, J., 3341        |
| Bone, E. A., 3388            | Hornberger, W., 3331     | Kubo, K., 3394, 3402       | O'Malley, P. J., 3319, 3423 | Sugiura, T., 3307           |
| Bonnet, P. A., 3353          | Horton, J. K., 3358      | Laurent, F., 3353          | Ornstein, P. L., 3319       | Swartling, D. J., 3369      |
| Born, L., 3341               | Hosoya, M., 3372         | Leach, C. A., 3413         | Parsons, M. E., 3413        | Takada, H., 3307            |
| Boucard, M., 3353            | Houghton, J. A., 3358    | Lefebvre, J., 3331         | Patil, S. D., 3372          | Takami, H., 3394, 3402      |
| Brown, T. H., 3413           | Houghton, P. J., 3358    | Lewis, C. N., 3388         | Pralong, E., 3423           | Theobald, C. J., 3413       |
| Buxton, D. P., 3349          | Ife, R. J., 3413         | Lodge, D., 3319, 3423      | Reavill, D. R., 3413        | Thimmaiah, K. N., 3358      |
| Calligaro, D. O., 3319, 3423 | Iguchi, S., 3307         | Lowe, P. R., 3377          | Rechenq, E., 3353           | Thomson, R. J., 3349        |
| Chapat, J. P., 3353          | Ishii, A., 3394, 3402    | Lucich, J. L., 3426        | Roos, I. A. G., 3349        | Todd, R. S., 3388           |
| Cheng, L., 3364              | Israel, M., 3358         | Mani, J. C., 3353          | Sablayrolles, C., 3353      | True, R. A., 3319           |
| Claeson, G., 3364            | Iwamura, H., 3307        | Matsui, T., 3307           | Salto, R., 3426             | Ushio, Y., 3307             |
| Clark, A. S., 3377           | James, A. M., 3349       | McQuaid, L. A., 3319, 3423 | San-nohe, K., 3325          | Wakelin, L. P. G., 3349     |
| Craik, C. S., 3426           | Kahl, S. B., 3426        | Meeson, M. L., 3413        | Sansom, C. E., 3377         | Webster, L. K., 3349        |
| Da, Y.-Z., 3382              | Kaiho, T., 3325          | Michel, A., 3353           | Sato, H., 3394, 3402        | Wiggall, K. J., 3413        |
| Davidson, A. H., 3388        | Kakkar, V. V., 3364      | Miki, I., 3394, 3402       | Sato, H., 3394, 3402        | Wikel, J. H., 3423          |
| Deacon, G. B., 3349          | Kamiya, J., 3325         | Mitch, C. H., 3319         | Schneller, S. W., 3372      | Williams, T. L., 3349       |
| DeCamp, D. L., 3426          | Karasawa, A., 3394, 3402 | Miyamoto, M., 3325         | Schoepp, D. D., 3319        | Yamazaki, S., 3307          |
| De Clercq, E., 3369, 3372    | Kato, T., 3325           | Mohri, S., 3402            | Schully, M. F., 3364        | Yokoyama, T., 3325          |
| DiMaio, J., 3331             | Kawakami, T., 3325       | Mori, H., 3325             | Schwalbe, C. H., 3377       | Yue, S. Y., 3331            |
|                              | Kawamura, M., 3307       | Mott, A. W., 3369          | Seshadri, R., 3358          |                             |
|                              | Keeling, D. J., 3413     | Munn, D., 3331             |                             |                             |




## Specific Inhibition of HIV-1 Protease by Boronated Porphyrins

The rapid spread of human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS), throughout the world has prompted an intense search for antiretroviral therapeutics. An analysis of nonpeptide compounds with useful pharmacological properties led us to test the ability of porphyrins to inhibit HIV protease (HIV PR). Determination of the  $IC_{50}$ 's of natural porphyrins on purified recombinant HIV-1 and HIV-2 PRs revealed that they are micromolar inhibitors of these enzymes. Availability of a series of carboxyl carborane ester derivatives of porphyrins synthesized as experimental neutron-capture therapeutics led to the discovery that compound 1, the tetrakis-carborane carboxylate ester of 2,4-bis-( $\alpha,\beta$ -dihydroxyethyl)deuteroporphyrin IX<sup>1,2</sup> (Table I), is a submicromolar inhibitor of HIV protease. This compound is also capable of inhibiting HIV-1 viral polyprotein processing in cultured mammalian cells (*ex vivo*).

The *in vitro* effect of the porphyrin derivatives on HIV-1 and HIV-2 PR activity was examined by monitoring the cleavage of a decapeptide substrate.<sup>3</sup> The  $IC_{50}$  values for a series of porphyrin-based compounds measured on HIV-1 and HIV-2 PRs are shown in Table I. Since many of the derivatives were insoluble in buffer alone, 5% DMSO was used to increase solubility and to allow a comparison of the binding affinities of the various compounds. The best inhibitor is 1, with an  $IC_{50}$  of 185 nM for HIV-1 PR and 700 nM for HIV-2 PR. The inhibitory potency of the porphyrin derivatives for HIV-2 PR is generally a factor of 2–5 less than for HIV-1 PR. Dipotassium salts of several of the inhibitors were soluble in aqueous solution and were assayed in the absence of DMSO. The  $IC_{50}$  values are shown in Table II.

The photosensitivity of 1 made the metalloporphyrin derivatives (3, 5, and 6) preferable for subsequent kinetic analysis. These were easily prepared in high yield by standard techniques, as described in the supplementary material. Initial enzyme rates were fit to the Michaelis-Menten equation and kinetic constants were calculated using a nonlinear regression program.<sup>4</sup> A Dixon plot for 5 is shown in Figure 1. The appearance of the intersecting inhibition curves is consistent with a competitive mode of inhibition, with an inhibition constant ( $K_i$ ) of  $140 \pm 25$  nM. Compound 3 also appears to be a competitive inhibitor, with a  $K_i$  of  $85 \pm 5$  nM (data not shown). The effect of salt concentration on inhibition by 3 was examined. The  $IC_{50}$  in 0.3 M NaCl (85 nM) was similar to the value obtained with 1 M NaCl (100 nM). This low ionic strength dependence of inhibition is important for *in vivo* applications.

The compounds assayed can be divided into three



**Figure 1.** Dixon plot of 5 inhibition of HIV-1 PR. Purified HIV-1 PR ( $6 \times 10^{-4}$  mg/mL) was incubated with 5 in 50 mM sodium acetate buffer, pH 5.5, containing 1 mM dithiothreitol, 1 mM EDTA, and 1 M NaCl. After 1 min, the substrate peptide was added to give the final substrate concentrations shown. The assay solutions were incubated for 30–45 min at 37 °C and enzyme activity was determined by quantitation of the hydrolysis products on HPLC.

classes: (1) carborane esters, (2) noncarborane esters, and (3) protoporphyrin IX. The best inhibitor *in vitro* is 1, which is esterified with four molecules of 1,2-dicarba-*closo*-dodecaboranecarboxylic acid. Although complexation with Co(II) or Cu(II) weakens binding about 10-fold, addition of Mn(III) has only 2-fold effect on inhibition, indicating that the hexacoordinate Mn(III) may be able to make favorable ionic interactions with the enzyme. Removal of all four carborane moieties, as in 12, substantially reduces inhibition. Removal of only two cages, as in 2, has little effect on binding. This suggests that only two of the four *closo*-carborane cages are responsible for most of the binding interaction. The metacarborane isomer, 9, binds approximately 60-fold less tightly, indicating that not only the presence of the carborane groups but also their isomeric conformation is important. Adding a methyl group to the unsubstituted carborane cage CH, as in 4, also substantially decreases the binding affinity. The carborane cages thus appear to have a specific interaction with HIV PR which results in high affinity between the molecule and enzyme. Replacement of the carborane cages with similarly sized but less hydrophobic groups such as benzoyl (10), adamantoyl (7), or even  $\beta$ -naphthoyl (11) groups gives inhibitors with  $IC_{50}$  values in the low micromolar range, suggesting the importance of supplying hydrophobic groups at these positions. The effect of the porphyrin derivatives on HIV-2 PR generally follows the same trend, with most of the  $IC_{50}$  values being several-fold higher.

The cytotoxicity of compounds ( $LD_{50}$ ) and their ability to inhibit capsid protein processing *ex vivo* during 4-h incubations ( $IC_{50}$ ) are shown in Table I. A plasmid which encodes the HIV-1 proviral genome, with the exception of the gp 160 envelope protein,<sup>5</sup> was stably introduced into the monkey cell line COS 7. Cloned progeny, COS A6 cells, constitutively release viral capsids into the media. Inhibition of polyprotein processing was determined by measuring the amount of p24 present in the viral capsid samples with an ELISA assay. The decrease in the amount of detectable p24 antigen correlated with a specific inhibition of HIV PR activity, as judged by the accumulation of capsid precursor in conjunction with a disappearance of the p24 mature protein band in Western blots (data not

- Hill, J. S.; Kahl, S. B.; Kaye, A. H.; Styli, S. S.; Koo, M.-S.; Gonzales, M. F.; Vardaxis, N. J.; Johnson, C. I. Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. *Proc. Natl. Sci. U.S.A.* **1992**, *89*, 1785–1789.
- Kahl, S. B.; Koo, M.-S. Synthesis of Tetrakis-carborane-carboxylate Esters of 2,4-Bis-( $\alpha,\beta$ -dihydroxyethyl)-deuteroporphyrin IX. *J. Chem. Soc., Chem. Commun.* **1990**, *24*, 1769–1771.
- DesJarlais, R. L.; Seibel, G. L.; Kuntz, I. D.; Furth, P. S.; Alvarez, J. C.; Ortiz de Montellano, P. R.; DeCamp, D. L.; Babé, L. M.; Craik, C. S. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 6644–6648.
- Leatherbarrow, R. J. Enzfitter. A Non-linear Regression Data Analysis Program for the IBM-PC. *Elsevier Biosoft*, Cambridge, U.K., 1987.

- Page, K. A.; Landau, N. R.; Littman, D. R. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. *J. Virol.* **1990**, *64*, 5270–5276.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.